INAHTA Listserv – *FOR MEMBERS ONLY, NOT FOR CIRCULATION*
Question & Answer Summary

Your agency experiences in dealing with individual participant data (IPD) meta-analysis (MA)?

Date of question: 25 Sept 2017
Origin of question: Carmen Moga, IHE, Canada
Background:
The HTA researchers at the IHE recently conducted an overview of systematic reviews which included both study-level systematic reviews and individual participant data (IPD) meta-analysis (MA). We are interested in the experience of other INAHTA members in dealing with IPD MA. We would be most grateful if you could help address any of the following questions:

1) Did your organization include, analyze, and report research evidence from IPD MA? If yes, what tool(s) did you use in judging the quality of an IPD MA? Please indicate the names and sources of the tool(s).
2) Did your organization conduct de novo IPD MA? If yes, please indicate the type of skills of the staff involved and an estimate time needed to accomplish the review.
3) Do you have any guidelines or processes in place for reviewing and reporting IPD MA? (Links to electronic copies of HTA reports or documents that describe the process would be very helpful.)
4) Are you collaborating with other research groups for assessing/conducting IPD MA?
5) Did you generally find that, compared with evidence from study-level systematic reviews, evidence from IPD MA provides greater confidence in drawing conclusions and additional value in the decision-making process?
6) What are your biggest challenges in assessing information from IPD MA?

Requested deadline for responses: 13 Oct 2017 or as soon as convenient
Please forward your response to the INAHTA Secretariat (INAHTA@ihe.ca) who will compile responses and report them all INAHTA members.

Responses:

CMeRC (Jani Mueller)	Sorry,we haven't done any.
G-BA (Matthias Perleth)	1) Occasionally, results from IPD MA are used in decision-making, together with other systematic reviews and MAs, however, G-BA does not conduct them 2) No 3) No, we rely on the assessment tools that are used for other systematic reviews, such as AMSTAR 4) No 5) We don't have any experience with such comparisons 6) We haven't identified specific challenges (yet)
CADTH (Ken Bond)	The people I have spoken with at CADTH are not aware of us ever conducting IPD analysis for its HTA (drug or device). If we have received any it would at most be 1 or 2, so our experience is limited. For the drug side (where IPD might actually occur), most drug trials are manufacturer-sponsored and they are reluctant to give patient-level data out for these analyses for many reasons.
DEFACTUM (Lotte Jensen)	We do not have any experience with this kind of reviews.
CEM (Nadine Berndt)	Sorry, no.

HAD-Uruguay (Ana Perez)	We have not yet experience with individual participant data meta-analysis.
IETS (Ines Ramirez Bermudez)	At IETS we haven´t performed any meta-analysis with individual participant data. Sometimes we have results of these studies in the discussion of our assessments, which are generally based on study-level systematic reviews.